✦ LIBER ✦

Different isoform patterns for vascular endothelial growth factor between clear cell and papillary renal cell carcinoma

✍ Scribed by JAN JACOBSEN; KJELL GRANKVIST; TORGNY RASMUSON; BÖRJE LJUNGBERG

Book ID: 109052496
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 149 KB
Volume: 97
Category: Article
ISSN: 1464-4096
DOI: 10.1111/j.1464-410x.2006.06138.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Difference between RAT and clear cell pa

Difference between RAT and clear cell papillary renal cell carcinoma/clear renal cell carcinoma

✍ Michal Michal; Ondrej Hes; Naoto Kuroda; Dmitry V. Kazakov; Milan Hora 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 41 KB

Different vascular endothelial growth fa

Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma

✍ BÖRJE J. LJUNGBERG; JAN JACOBSEN; STINA HÄGGSTRÖM RUDOLFSSON; GUDRUN LINDH; KJEL 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB

Circulating biomarkers for vascular endo

Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma

✍ Amado J. Zurita; Eric Jonasch; Hua-Kang Wu; Hai T. Tran; John V. Heymach 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 201 KB 👁 1 views

Vascular endothelial growth factor-targe

Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma

✍ Brian I. Rini 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 276 KB 👁 2 views

Expression of vascular endothelial growt

Expression of vascular endothelial growth factor protein in human renal cell carcinoma

✍ J. Jacobsen; K. Grankvist; T. Rasmuson; A. Bergh; G. Landberg; B. Ljungberg 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 430 KB

Clinical factors associated with outcome

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy

✍ Toni K. Choueiri; Jorge A. Garcia; Paul Elson; Mohamad Khasawneh; Saif Usman; Al 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

## Abstract ## BACKGROUND. Therapy targeted against the vascular endothelial growth factor (VEGF) pathway is a standard of care for patients with metastatic renal cell carcinoma (RCC). The identification of patients who are more likely to benefit from these agents is warranted. ## METHODS. In to